Introduction: Cisplatin (CDDP) is an effective and widely used chemotherapeutic agent for pediatric tumors, and ototoxicity is one of the dose-limiting side effects. Objective: It was the aim of our study to investigate the effect of acetyl L-carnitine (ALCAR) on experimental CDDP ototoxicity by audiologic tests, histomorphologic, immunohistochemical and ultrastructural examinations and to investigate the apoptotic pathways. Materials and Methods: Wistar albino rats (n = 28) were studied. Baseline audiological tests were performed in 4 groups: group 1, control; group 2, ALCAR; group 3, CDDP; group 4, CDDP + ALCAR-administered rats. Control audiological tests were performed on the 3rd day, and then the rats were sacrificed. Ear and brain specimens were examined by transmission electron microscopy, and caspase 3, 8 and 9 activities were investigated. Results: The CDDP-administered rats showed significant auditory brainstem response threshold shifts using all stimuli (clicks, 6-kHz and 8-kHz tone burst) compared with the control groups. The CDDP + ALCAR-administered rats showed significant auditory brainstem response threshold shifts by only click stimuli compared with the control groups. In the brain, spiral ganglion and organ of Corti, ultrastructural damage was prominent in group 3; the number of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)-positive cells and caspase 3, 8 and 9 immunostaining cells was significantly high in group 3. Conclusion: ALCAR improves CDDP-induced auditory impairment, and also antioxidative and antiapoptotic properties of ALCAR on CDDP ototoxicity were supported by the findings.

Keywords:
Cisplatin ototoxicity, Cisplatin neurotoxicity, Acetyl L-carnitine, Apoptosis, Ultrastructural findings
1.
Adamson PC, Balis FM, Berg S, Blaney SM: General principles of chemotherapy; in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, Lippincott, Williams & Wilkins, 2006, pp 290–365.
2.
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649–655.
3.
Brock P, Pritchard J, Bellman S, Pinkerton CR: Ototoxicity of high-dose cis-platinum in children. Med Pediatr Oncol 1988;16:368–369.
4.
Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J: Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991;19:295–300.
5.
McHaney VA, Thibadoux G, Hayes FA, Green AA: 1983. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983;102:314–317.
6.
Skinner R: Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 2004;40:2352–2354.
7.
Clerici WJ, Hensley K, DiMartino DL, Butterfield DA: Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 1996;98:116–124.
8.
Rybak LP, Husain K, Morris C, Whitworth C, Somani S: Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21:513–520.
9.
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157–167.
10.
Kitada N, Takara K, Itoh C, Minegaki T, Tsujimoto M, Sakaeda T, Yokoyama T: Comparative analysis of cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells. Chemotherapy 2008;54:217–223.
11.
Yin HY, Ma XF, Liu F, Xia M, Xu AT: Protective effect of geranylgeranylacetone on cisplatin ototoxicity. Chemotherapy 2009;55:1–5.
12.
Bremer J: Carnitine-metabolism and functions. Physiol Rev 1983;63:1420–1480.
13.
Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA: Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem 2006;17:73–88.
14.
Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005;41:1746–1750.
15.
De Grandis D: Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007;21(suppl 1):39–43, discussion 45–46.
16.
Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135–138.
17.
Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G: Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9:5756–5767.
18.
Altun ZS, Güneş D, Aktaş S, Erbayraktar Z, Olgun N: Protective effects of acetyl-L-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem Res 2010;35:437–443.
19.
Di Cesare Mannelli L, Ghelardini C, Calvani M, Nicolai R, Mosconi L, Vivoli E, Pacini A, Bartolini A: Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci 2007;26:820–827.
20.
Pillich RT, Scarsella G, Risuleo G: Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-L-carnitine to mouse fibroblasts in culture. Exp Cell Res 2005;306:1–8.
21.
Zhu X, Sato EF, Wang Y, Nakamura H, Yodoi J, Inoue M: Acetyl-L-carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 2008;478:154–160.
22.
Tüfekçi Ö, Gunes D, Özoğul C, Kolatan E, Altun Z, Yılmaz O, Aktaş S, Erbayraktar Z, Kırkım G, Mutafoğlu K, Soylu A, Şerbetçioğlu B, Güneri EA, Olgun N: Evaluation of the effect of acetyl-L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451–459.
23.
Akdogan O, Selcuk A, Take G, Erdoğan D, Dere H: Continuous or intermittent noise exposure, does it cause vestibular damage? An experimental study. Auris Nasus Larynx 2009;36:2–6.
24.
Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben RJ, Rybak L, Van de Water TR: Use of organotypic cultures of Corti’s organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997;18:559–571.
25.
Liu W, Staecker H, Stupak H, Malgrange B, Lefebvre P, Van De Water TR: Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 1998;9:2609–2614.
26.
Huang T, Cheng AG, Stupak H, Liu W, Kim A, Staecker H, Lefebvre PP, Malgrange B, Kopke R, Moonen G, Van De Water TR: Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci 2000;18:259–270.
27.
Cardinaal RM, de Groot JC, Huizing EH, Veldman JE, Smoorenburg GF: Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res 2000;144:135–146.
28.
Jordan P, Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000;57:1229–1235.
29.
Huang X, Whitworth CA, Rybak LP: Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol 2007;28:828–833.
30.
Alam SA, Ikeda K, Oshima T, Suzuki M, Kawase T, Kikuchi T, Takasaka T: Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 2000;141:28–38.
31.
Teranishi M, Nakashima T, Wakabayashi T: Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res 2001;151:61–70.
32.
Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998;281:1305–1308.
33.
Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899–1911.
34.
Harris MH, Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000;7:1182–1191.
35.
Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998;281:1312–1316.
36.
Matsui JI, Ogilvie JM, Warchol ME: Inhibition of caspases prevents ototoxic and ongoing hair cell death. J Neurosci 2002;22:1218–1227.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.